Please Wait.....
Report
Europe Blood Glucose Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)
Market Report I 2026-01-16 I 95 Pages I Mordor Intelligence
Europe Blood Glucose Monitoring Market Analysis
The Europe blood glucose monitoring market is expected to grow from USD 5.61 billion in 2025 to USD 6.07 billion in 2026 and is forecast to reach USD 9.04 billion by 2031 at 8.28% CAGR over 2026-2031. The region is shifting from episodic finger-stick testing toward integrated continuous glucose monitoring as statutory payers expand coverage and device accuracy improves. Convergence of sensors, cloud platforms and automated insulin delivery strengthens clinical outcomes while streamlining daily management for millions living with diabetes. Germany's statutory health insurance contracts and the United Kingdom's artificial-pancreas rollout validate scalable reimbursement blueprints, whereas Nordic programs showcase data-sharing frameworks that accelerate remote care. Intensifying competition, reinforced by a 10-year patent truce between Abbott and Dexcom, is spurring next-generation features such as predictive analytics, longer sensor life and non-invasive form factors. Supply-chain risk management, notably under new European Commission notice rules, now shapes procurement strategy as much as raw innovation.
Europe Blood Glucose Monitoring Market Trends and Insights
Ageing Population Drives Unprecedented Diabetes Burden Across European Demographics
An ageing population enlarges the addressable base of users for Europe blood glucose monitoring market devices. Scientific Reports confirms that 61 million Europeans aged 20-79 live with diabetes, with projections indicating 69 million by 2045. Eastern and Southern economies exhibit the steepest comorbidity indices, concentrating demand into health systems with limited fiscal capacity. NHS England data registers half a million newly identified people at high risk of type 2 diabetes in 1 year, underscoring preventive screening momentum. The demographic wave supports multisector collaboration on earlier detection, remote follow-up and coaching. Over the long term, risk-stratified programs are expected to anchor stable device utilisation and recurring sensor revenues across the continent.
Technology Convergence Eliminates Traditional CGM-SMBG Boundaries Through Accuracy Innovations
European clinicians now compare continuous and capillary monitoring on equal analytical footing as sensor MARD falls below 9%. Dexcom G7 records an 8.0% MARD with a 15.5-day wear period. Abbott FreeStyle Libre 3 streams glucose every minute over 14 days, while Medtronic's MiniMed 780G auto-adjusts insulin every 5 minutes, eliminating routine finger-stick confirmation. Roche gained CE Mark for its Accu-Chek SmartGuide CGM with AI-driven hypoglycaemia prediction in July 2024. FDA iCGM rules now benchmark accuracy across populations, further harmonising evidence requirements. Together, these milestones dissolve historical silos between SMBG and CGM device classes and lift replacement cycles.
High CGM Device Costs Create Access Barriers Despite Proven Clinical Benefits
Unit economics remain a hurdle for budget-constrained systems in Eastern and Southern Europe. France's 2025 Social Security Financing Law already projects a EUR 22 billion deficit even as health insurance outlays rise 3.4% to EUR 265.9 billion. A French cost-utility study finds CGM adds EUR 4.6 million in device costs yet lowers long-run admissions, yielding net savings over the forecast horizon. Still, Dexcom identifies limited funding and restrictive inclusion rules as top adoption barriers in its 2025 European clinician survey. German insurers require independent medical reviews to validate intensive insulin use before approving CGM, adding administrative friction. These cost concerns temper otherwise strong demand trajectories.
Other drivers and restraints analyzed in the detailed report include:
European Reimbursement Revolution Unlocks CGM Access for Type 2 Diabetes PopulationsDigital Health Platform Integration Transforms Diabetes Management Through Remote Monitoring CapabilitiesSemiconductor MEMS Supply Chain Constraints Threaten Medical Device Production Continuity
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Self-monitoring blood glucose preserved 59.85% Europe blood glucose monitoring market share in 2025 due to low upfront cost and entrenched clinical routines. Single-use test strips remain the highest-volume consumable, especially across primary care for type 2 patients managing weight and oral medication. Nonetheless, the continuous glucose monitoring segment increases at a 14.80% CAGR to 2031 and now anchors most strategic investment. Europe blood glucose monitoring market size for CGM sensors alone is projected to add USD 1.36 billion between 2026 and 2031, reflecting transitions from early adopters to mainstream prescriptions. Breakthrough accuracy gains - Dexcom G7's 8.0% MARD and Abbott Libre 3's one-minute transmission - elevate clinical confidence and simplify reimbursement dossiers. Integration with insulin pumps, as in Omnipod 5's linkage to Libre 2 Plus, further blurs hardware boundaries.
Durable components such as transmitters and receivers underpin recurring sensor revenue, while algorithm licences emerge as a nascent value pool. Non-invasive optics, led by DiaMonTech and EU-funded Talisman prototypes, promise step-change convenience if precision thresholds are met. FDA iCGM regulation now harmonises performance trials, encouraging SMBG incumbents like Roche to re-enter with AI-enabled platforms. Collectively, these shifts redirect R&D budgets from strip chemistry to sensor firmware, real-time analytics and cloud connectivity, reshaping supply chains and distributor training curricula.
The Europe Blood Glucose Monitoring Market Report is Segmented by Device Type (Self-Monitoring Blood Glucose Devices [Glucometer Devices, Test Strips, and Lancets] and Continuous Glucose Monitoring Devices [Sensors and Durables]), End User (Home Healthcare, Hospitals & Clinics, and Pharmacies & Others), and Geography (Germany, France, United Kingdom, Italy, Spain and More). The Market Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Abbott Laboratories Roche Dexcom Medtronic Ascensia Lifescan Senseonics, Inc. Ypsomed Nova Biomedical Nipro I-Sens Arkray AgaMatrix Bionime Acon Labs Rossmax Terumo Trividia Health Medisana
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Ageing & Diabetes Prevalence Surge
4.2.2 CGM-SMBG Technology Convergence & Accuracy Gains
4.2.3 Expanded Public Reimbursement For CGM Sensors
4.2.4 Digital-Health Platform Integration & Remote Monitoring
4.2.5 Raising Need Of Hypoglycaemia Monitoring
4.3 Market Restraints
4.3.1 High Cost Of CGM Devices & Consumables
4.3.2 Semiconductor MEMS Supply-Chain Constraints
4.3.3 GDPR Data-Privacy Compliance Burden
4.4 Regulatory Landscape
4.5 Porter's Five Forces
4.5.1 Bargaining Power of Suppliers
4.5.2 Bargaining Power of Consumers
4.5.3 Threat of New Entrants
4.5.4 Threat of Substitutes
4.5.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (value, USD)
5.1 By Device Type
5.1.1 Self-Monitoring Blood Glucose Devices
5.1.1.1 Glucometer Devices
5.1.1.2 Test Strips
5.1.1.3 Lancets
5.1.2 Continuous Glucose Monitoring Devices
5.1.2.1 Sensors
5.1.2.2 Durables
5.2 By End User
5.2.1 Home Healthcare
5.2.2 Hospitals & Clinics
5.2.3 Pharmacies & Others
5.3 Geography
5.3.1 Germany
5.3.2 France
5.3.3 United Kingdom
5.3.4 Italy
5.3.5 Spain
5.3.6 Rest of Europe
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
6.3.1 Abbott Laboratories
6.3.2 F. Hoffmann-La Roche
6.3.3 Dexcom Inc.
6.3.4 Medtronic plc
6.3.5 Ascensia Diabetes Care
6.3.6 LifeScan Inc.
6.3.7 Senseonics, Inc.
6.3.8 Ypsomed AG
6.3.9 Nova Biomedical
6.3.10 Nipro
6.3.11 i-Sens
6.3.12 Arkray
6.3.13 Agamatrix
6.3.14 Bionime
6.3.15 Acon Labs
6.3.16 Rossmax
6.3.17 Terumo
6.3.18 Trividia Health
6.3.19 Medisana
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security